Asthma therapy for children under 5 years of age

Current Opinion in Pulmonary Medicine

Volumn 12, Issue 1, 2006, Pages 34-41

  Boehmer, Annemie L M ^a   Merkus, Peter J F M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Asthma; Beta z receptor agonists; Corticosteroids; Leucotriene receptor antogonists; Wheeze; Young children

Indexed keywords

ALLERGEN; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DEXAMETHASONE; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; ANTIASTHMATIC AGENT;

ASTHMA; BONE DISEASE; BONE METABOLISM; CLINICAL TRIAL; COUGHING; DIAGNOSTIC ACCURACY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; GROWTH DISORDER; HUMAN; INFANT; INFLAMMATION; LUNG FUNCTION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PHENOTYPE; PRESCHOOL CHILD; REVIEW; RISK FACTOR; SMOKING; SYMPTOM; WHEEZING; ABNORMAL RESPIRATORY SOUND; FEMALE; INHALATIONAL DRUG ADMINISTRATION; MALE; NEWBORN;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD, PRESCHOOL; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKOTRIENE ANTAGONISTS; MALE; RESPIRATORY SOUNDS;

EID: 33646853683     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000199810.42011.8e     Document Type: Review

References (83)

1. Silverman M. Wheezing disorders in infants and young children. In: Silverman M, editor. Childhood asthma and other wheezing disorders. London: Arnold; 2002. pp. 307-332.
2. Warner JO, Marguet C, Rao R, et al. Inflammatory mechanisms in childhood asthma. Clin Exp Allergy 1998; 28 (Suppl 5):71-75; discussion 90-91.
3. Morgan WJ, Stern DA, Sherrill DL, et al. Outcome of asthma and wheezing in the first six years of life: follow-up through adolescence. Am J Respir Crit Care Med 2005; 172:1253-1258.
4. Martinez F. Clinical features of the wheezy infant. In: Martinez F, Godfrey S, editors. Wheezing disorders in the preschool child. New York: Martin Dunitz; 2003. pp. 55-72.
5. Stein RT, Martinez FD. Asthma phenotypes in childhood: lessons from an epidemiological approach. Paediatr Respir Rev 2004; 5:155-161.
6. Roorda RJ, Mezei G, Bisgaard H, Maden C. Response of preschool children with asthma symptoms to fluticasone propionate. J Allergy Clin Immunol 2001; 108:540-546.
7. Kanengiser S, Dozor AJ. Forced expiratory maneuvers in children aged 3 to 5 years. Pediatr Pulmonol 1994; 18:144-149.
8. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000; 162 (4 Pt 1):1403-1406.
9. Hogg C, Bush A. Childhood asthma: all that wheezes is not inflammation. Clin Exp Allergy 1997; 27:991-994.
10. Taussig LM, Wright AL, Holberg CJ, et al. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol 2003; 111:661-675; quiz 676.
11. Hofhuis W, de Jongste JC, Merkus PJ. Adverse health effects of prenatal and postnatal tobacco smoke exposure on children. Arch Dis Child 2003; 88:1086-1090.
12. Tappin DM, Lumsden MA, Gilmour WH, et al. Randomised controlled trial of home based motivational interviewing by midwives to help pregnant smokers quit or cut down. BMJ 2005; 331:373-377.
13. Gdalevich M, Mimouni D, Mimouni M. Breast-feeding and the risk of bronchial asthma in childhood: a systematic review with meta-analysis of prospective studies. J Pediatr 2001; 139:261-266.
14. Chavasse R, Seddon P, Bara A, McKean M. Short acting beta agonists for recurrent wheeze in children under 2 years of age. Cochrane Database Syst Rev 2002; (3):CD002873.
15. Kraemer R, Frey U, Sommer CW, Russi E. Short-term effect of albuterol, delivered via a new auxiliary device, in wheezy infants. Am Rev Respir Dis 1991; 144:347-351.
16. Alario AJ, Lewander WJ, Dennehy P, et al. The efficacy of nebulized metaproterenol in wheezing infants and young children. Am J Dis Child 1992; 146:412-418.
17. Bentur L, Canny GJ, Shields MD, et al. Controlled trial of nebulized albuterol in children younger than 2 years of age with acute asthma. Pediatrics 1992; 89:133-137.
18. Sly PD, Lanteri CJ, Raven JM. Do wheezy infants recovering from bronchiolitis respond to inhaled salbutamol? Pediatr Pulmonol 1991; 10:36-39.
19. Clarke JR, Aston H, Silverman M. Delivery of salbutamol by metered dose inhaler and valved spacer to wheezy infants: effect on bronchial responsiveness. Arch Dis Child 1993; 69:125-129.
20. Hayden MJ, Wildhaber JH, LeSouef PN. Bronchodilator responsiveness testing using raised volume forced expiration in recurrently wheezing infants. Pediatr Pulmonol 1998; 26:35-41.
21. Chavasse RJ, Bastian-Lee Y, Richter H, et al. Inhaled salbutamol for wheezy infants: a randomised controlled trial. Arch Dis Child 2000; 82:370-375.
22. O'Callaghan C, Milner AD, Swarbrick A. Paradoxical deterioration in lung function after nebulised salbutamol in wheezy infants. Lancet 1986; 2:1424-1425.
23. Prendiville A, Green S, Silverman M. Paradoxical response to nebulised salbutamol in wheezy infants, assessed by partial expiratory flow-volume curves. Thorax 1987; 42:86-91.
24. Hofhuis W, van der Wiel EC, Tiddens HA, et al. Bronchodilation in infants with malacia or recurrent wheeze. Arch Dis Child 2003; 88:246-249.
25. Tiddens HA, Hofhuis W, Bogaard JM, et al. Compliance, hysteresis, and collapsibility of human small airways. Am J Respir Crit Care Med 1999; 160:1110-1118.
26. Lodrup Carlsen KC, Pettersen M, Carlsen KH. Is bronchodilator response in 2-yr-old children associated with asthma risk factors? Pediatr Allergy Immunol 2004; 15:323-330.
27. Teper AM, Kofman CD, Szulman GA, et al. Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma. Am J Respir Crit Care Med 2005; 171:587-590. The risk factors that have been chosen by these authors are indicative for wheezing phenotypes that respond to ICSs.
28. Saglani S, Malmstrom K, Pelkonen AS, et al. Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am J Respir Crit Care Med 2005; 171:722-727. First study combining inflammatory patterns and airway histology in very young, well characterized wheezing children.
29. Warnings for asthma drugs. Lancet 2005; 366:266.
30. Sekhsaria S, Alam M, Sait T, et al. Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5. J Asthma 2004; 41:575-582.
31. McDonald NJ, Bara AI. Anticholinergic therapy for chronic asthma. Cochrane Database Syst Rev 2003; (3):CD003535.
32. Everard M, Bara A, Kurian M, et al. Anticholinergic drugs for wheeze in children under the age of two years. Cochrane Database Syst Rev 2005; (3):CD001279.
33. Haahtela T. Early treatment of asthma. Allergy 1999; 54 (Suppl 49):74-81.
34. Rytila P, Pelkonen AS, Metso T, et al. Induced sputum in children with newly diagnosed mild asthma: the effect of 6 months of treatment with budesonide or disodium cromoglycate. Allergy 2004; 59:839-844.
35. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis 1992; 146:547-554.
36. Merkus PJFM, van Pelt W, van Houwelingen JC, et al. Inhaled corticosteroids and growth of airway function in asthmatic children. Eur Respir J 2004; 23:861-868.
37. Wilson N, Sloper K, Silverman M. Effect of continuous treatment with topical corticosteroid on episodic viral wheeze in preschool children. Arch Dis Child 1995; 72:317-320.
38. Doull IJ, Lampe FC, Smith S, et al. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial. BMJ 1997; 315:858-862.
39. Grunberg K, Sharon RF, Sont JK, et al. Rhinovirus-induced airway inflammation in asthma: effect of treatment with inhaled corticosteroids before and during experimental infection. Am J Respir Crit Care Med 2001; 164 (10 Pt 1):1816-1822.
40. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000; (2):CD001107.
41. Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child 1990; 65:407-410.
42. Svedmyr J, Nyberg E, Thunqvist P, et al. Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Acta Paediatr 1999; 88:42-47.
43. Maayan C, Itzhaki T, Bar-Yishay E, et al. The functional response of infants with persistent wheezing to nebulized beclomethasone dipropionate. Pediatr Pulmonol 1986; 2:9-14.
44. Bisgaard H, Munck SL, Nielsen JP, et al. Inhaled budesonide for treatment of recurrent wheezing in early childhood. Lancet 1990; 336:649-651.
45. Noble V, Ruggins NR, Everard ML, Milner AD. Inhaled budesonide for chronic wheezing under 18 months of age. Arch Dis Child 1992; 67:285-288.
46. Connett GJ, Warde C, Wooler E, Lenney W. Use of budesonide in severe asthmatics aged 1-3 years. Arch Dis Child 1993; 69:351-355.
47. Kraemer R, Graf Bigler U, Casaulta Aebischer C, et al. Clinical and physiological improvement after inhalation of low-dose beclomethasone dipropionate and salbutamol in wheezy infants. Respiration 1997; 64:342-349.
48. Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am J Respir Crit Care Med 1999; 160:126-131.
49. Bisgaard H, Allen D, Milanowski J, et al. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004; 113:e87-e94.
50. Teper AM, Colom AJ, Kofman CD, et al. Effects of inhaled fluticasone proproinate in children less than 2 years old with recurrent wheezing. Pediatr Pulmonol 2004; 37:111-115.
51. Van Bever HP, Schuddinck L, Wojciechowski M, Stevens WJ. Aerosolized budesonide in asthmatic infants: a double blind study. Pediatr Pulmonol 1990; 9:177-180.
52. Stick SM, Burton PR, Clough JB, et al. The effects of inhaled beclomethasone dipropionate on lung function and histamine responsiveness in recurrently wheezy infants. Arch Dis Child 1995; 73:327-332.
53. Barrueto L, Mallol J, Figueroa L. Beclomethasone dipropionate and salbutamol by metered dose inhaler in infants and small children with recurrent wheezing. Pediatr Pulmonol 2002; 34:52-57.
54. Moeller A, Franklin P, Hall GL, et al. Inhaled fluticasone dipropionate decreases levels of nitric oxide in recurrently wheezy infants. Pediatr Pulmonol 2004; 38:250-255.
55. Hofhuis W, van der Wiel EC, Nieuwhof EM, et al. Efficacy of fluticasone propionate on lung function and symptoms in wheezy infants. Am J Respir Crit Care Med 2005; 171:328-333. As this study shows no effect of ICSs with the use of infant lung function, it provides arguments not to prescribe ICSs in every wheezing child.
56. Merkus PJFM and De Jongste JC. Inhaled corticosteroids in wheezy infants [letter to the editor]. Am J Crit Care Med 2005; 172:1058-1059.
57. Kovar J, Willet KE, Hislop A, Sly PD. Impact of postnatal glucocortocoids on early lung development. J Appl Physiol 2005; 98:881-888.
58. Brand PL. Inhaled corticosteroids reduce growth: or do they? Eur Respir J 2001; 17:287-294.
59. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics - 2002. J Allergy Clin Immunol 2002; 110 (5 Suppl):S141-S219.
60. Jeffery P. Inflammation and remodeling in the adult and child with asthma. Pediatr Pulmonol Suppl 2001; 21:3-16.
61. Szefler SJ. Airway remodeling: therapeutic target or not? Am J Respir Crit Care Med 2005; 171:672-673.
62. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159 (4 Pt 1):1043-1051.
63. van den Toorn LM, Prins JB, de Jongste JC, et al. Benefit from antiinflammatory treatment during clinical remission of atopic asthma. Respir Med 2005; 99:779-787.
64. Pedersen S, Silverman M, Martinez F. The background to early intervention. Childhood asthma. Eur Respir J Suppl 1998; 27:1s-2s.
65. Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 2005; 116:477-486.
66. Payne DN, Rogers AV, Adelroth E, et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Respir Crit Care Med 2003; 167:78-82.
67. Pohunek P, Warner JO, Turzikova J, et al. Markers of eosinophilic inflammation and tissue re-modelling in children before clinically diagnosed bronchial asthma. Pediatr Allergy Immunol 2005; 16:43-51.
68. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005; 172:453-459.
69. Brussee JE, Smit HA, Kerkhof M, et al. Exhaled nitric oxide in 4-year-old children: relationship with asthma and atopy. Eur Respir J 2005; 25:455-461.
70. Ratjen F, Kavuk I, Gartig S, et al. Airway nitric oxide in infants with acute wheezy bronchitis. Pediatr Allergy Immunol 2000; 11:230-235.
71. Payne DN. Nitric oxide in allergic airway inflammation. Curr Opin Allergy Clin Immunol 2003; 3:133-137.
72. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in asthmatic children: a randomized controlled trial. Am J Respir Crit Care Med 2005; 172:831-836.
73. Straub DA, Moeller A, Minocchieri S, et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 2005; 25:289-294. Important because of choice of study endpoints of exhaled nitric oxide and infant lung function.
74. Koller DY, Wojnarowski C, Herkner KR, et al. High levels of eosinophil cationic protein in wheezing infants predict the development of asthma. J Allergy Clin Immunol 1997; 99 (6 Pt 1):752-756.
75. Webb MS, Henry RL, Milner AD. Oral corticosteroids for wheezing attacks under 18 months. Arch Dis Child 1986; 61:15-19.
76. Daugbjerg P, Brenoe E, Forchhammer H, et al. A comparison between nebulized terbutaline, nebulized corticosteroid and systemic corticosteroid for acute wheezing in children up to 18 months of age. Acta Paediatr 1993; 82:547-551.
77. van Woensel JB, Wolfs TF, van Aalderen WM, et al. Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis. Thorax 1997; 52:634-637.
78. Garrison MM, Christakis DA, Harvey E, et al. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics 2000; 105:E44.
79. Schuh S, Coates AL, Binnie R, et al. Efficacy of oral dexamethasone in outpatients with acute bronchiolitis. J Pediatr 2002; 140:27-32.
80. Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet 2003; 362:1433-1438.
81. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leucotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108:E48.
82. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003; 167:379-383.
83. Straub DA, Minocchieri S, Moeller A, et al. The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest 2005; 127:509-514. Important because of choice of study endpoints of exhaled nitric oxide and infant lung function.